XOMA Royalty Valuation
Is XOMA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of XOMA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate XOMA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate XOMA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for XOMA?
Key metric: As XOMA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is XOMA's PS Ratio? | |
|---|---|
| PS Ratio | 16.5x |
| Sales | US$21.61m |
| Market Cap | US$354.31m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 15.3x |
| Enterprise Value/EBITDA | -21.8x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does XOMA's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 28.6x | ||
RGNX REGENXBIO | 5.6x | 36.3% | US$454.8m |
PGEN Precigen | 66.7x | 62.5% | US$264.4m |
MGTX MeiraGTx Holdings | 33.3x | 46.8% | US$462.7m |
ITOS iTeos Therapeutics | 8.7x | 56.3% | US$297.0m |
XOMA XOMA Royalty | 16.5x | 31.3% | US$354.3m |
Price-To-Sales vs Peers: XOMA is good value based on its Price-To-Sales Ratio (16.5x) compared to the peer average (28.6x).
Price to Sales Ratio vs Industry
How does XOMA's PS Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: XOMA is expensive based on its Price-To-Sales Ratio (16.5x) compared to the US Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is XOMA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 16.5x |
| Fair PS Ratio | 7.2x |
Price-To-Sales vs Fair Ratio: XOMA is expensive based on its Price-To-Sales Ratio (16.5x) compared to the estimated Fair Price-To-Sales Ratio (7.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$30.20 | US$86.00 +184.8% | 36.0% | US$117.00 | US$55.00 | n/a | 2 |
| Nov ’25 | US$30.38 | US$83.00 +173.2% | 41.0% | US$117.00 | US$49.00 | n/a | 2 |
| Oct ’25 | US$27.14 | US$83.00 +205.8% | 41.0% | US$117.00 | US$49.00 | n/a | 2 |
| Sep ’25 | US$29.25 | US$83.00 +183.8% | 41.0% | US$117.00 | US$49.00 | n/a | 2 |
| Aug ’25 | US$25.77 | US$58.00 +125.1% | 27.6% | US$74.00 | US$42.00 | n/a | 2 |
| Jul ’25 | US$24.90 | US$58.00 +132.9% | 27.6% | US$74.00 | US$42.00 | n/a | 2 |
| Jun ’25 | US$25.79 | US$58.00 +124.9% | 27.6% | US$74.00 | US$42.00 | n/a | 2 |
| May ’25 | US$25.82 | US$57.00 +120.8% | 29.8% | US$74.00 | US$40.00 | n/a | 2 |
| Feb ’24 | US$20.30 | US$62.50 +207.9% | 10.4% | US$69.00 | US$56.00 | US$20.60 | 2 |
| Jan ’24 | US$18.40 | US$62.50 +239.7% | 10.4% | US$69.00 | US$56.00 | US$18.50 | 2 |
| Dec ’23 | US$23.14 | US$62.50 +170.1% | 10.4% | US$69.00 | US$56.00 | US$15.38 | 2 |
| Nov ’23 | US$17.12 | US$62.50 +265.1% | 10.4% | US$69.00 | US$56.00 | US$19.13 | 2 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
Kiniksa Pharmaceuticals International
US$1.5b
A biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide.
KNSA
US$21.28
7D
-0.05%
1Y
33.2%
Spectrum Pharmaceuticals
US$209.9m
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.
SPPI
US$1.03
7D
5.3%
1Y
17.0%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$17.12
7D
4.2%
1Y
79.3%